Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 31

1.

High expectancy and early response produce optimal effects in sertraline treatment for post-traumatic stress disorder.

Graham B, Garcia NM, Burton MS, Cooper AA, Roy-Byrne PP, Mavissakalian MR, Feeny NC, Zoellner LA.

Br J Psychiatry. 2018 Dec;213(6):704-708. doi: 10.1192/bjp.2018.211. Epub 2018 Oct 25.

PMID:
30355364
2.

Do changes in trauma-related beliefs predict PTSD symptom improvement in prolonged exposure and sertraline?

Cooper AA, Zoellner LA, Roy-Byrne P, Mavissakalian MR, Feeny NC.

J Consult Clin Psychol. 2017 Sep;85(9):873-882. doi: 10.1037/ccp0000220. Epub 2017 May 15.

3.

What would you choose? Sertraline or prolonged exposure in community and PTSD treatment seeking women.

Feeny NC, Zoellner LA, Mavissakalian MR, Roy-Byrne PP.

Depress Anxiety. 2009;26(8):724-31. doi: 10.1002/da.20588.

4.

Early detection of relapse in panic disorder.

Mavissakalian MR, Guo S.

Acta Psychiatr Scand. 2004 Nov;110(5):393-9.

PMID:
15458563
5.

Cost effectiveness of acute imipramine therapy versus two imipramine maintenance treatment regimens for panic disorder.

Mavissakalian MR, Schmier JK, Flynn JA, Revicki DA.

Pharmacoeconomics. 2000 Oct;18(4):383-91.

PMID:
15344306
6.

Switching from imipramine to sertraline in panic disorder.

Mavissakalian MR.

J Psychiatr Pract. 2004 Mar;10(2):88-94.

PMID:
15330404
7.

Imipramine vs. sertraline in panic disorder: 24-week treatment completers.

Mavissakalian MR.

Ann Clin Psychiatry. 2003 Sep-Dec;15(3-4):171-80.

PMID:
14971862
8.

Sertraline in panic disorder: initial treatment versus switch strategy.

Mavissakalian MR.

J Clin Psychopharmacol. 2003 Dec;23(6):646-51.

PMID:
14624193
9.

Long-term maintenance and discontinuation of imipramine therapy in panic disorder with agoraphobia.

Mavissakalian MR, Perel JM.

Arch Gen Psychiatry. 1999 Sep;56(9):821-7.

PMID:
12884888
10.

Duration of imipramine therapy and relapse in panic disorder with agoraphobia.

Mavissakalian MR, Perel JM.

J Clin Psychopharmacol. 2002 Jun;22(3):294-9.

PMID:
12006900
11.

Predictors of entering a long-term drug treatment study of panic disorder.

Mavissakalian MR, Guo S.

Compr Psychiatry. 2002 Mar-Apr;43(2):88-94.

PMID:
11893985
12.

2nd year maintenance and discontinuation of imipramine in panic disorder with agoraphobia.

Mavissakalian MR, Perel JM.

Ann Clin Psychiatry. 2001 Jun;13(2):63-7.

PMID:
11534926
13.

The side effects burden of extended imipramine treatment of panic disorder.

Mavissakalian MR, Perel JM.

J Clin Psychopharmacol. 2000 Oct;20(5):547-55.

PMID:
11001240
14.

Generalized anxiety disorder versus panic disorder: participation in controlled efficacy trials.

Mavissakalian MR, Zamar N.

Compr Psychiatry. 2000 Jul-Aug;41(4):253-8.

PMID:
10929792
15.

Rational treatment of panic disorder with antidepressants.

Mavissakalian MR, Ryan MT.

Ann Clin Psychiatry. 1998 Dec;10(4):185-95. Review.

PMID:
9988061
16.

Gauging the effectiveness of extended imipramine treatment for panic disorder with agoraphobia.

Mavissakalian MR, Perel JM, Talbott-Green M, Sloan C.

Biol Psychiatry. 1998 Jun 1;43(11):848-54.

PMID:
9611676
17.

Life events and panic disorder/agoraphobia: a comparison at two time periods.

Lteif GN, Mavissakalian MR.

Compr Psychiatry. 1996 Jul-Aug;37(4):241-4.

PMID:
8826687
18.

Phenomenology of panic attacks: responsiveness of individual symptoms to imipramine.

Mavissakalian MR.

J Clin Psychopharmacol. 1996 Jun;16(3):233-7.

PMID:
8784655
19.

The relationship of plasma imipramine and N-desmethylimipramine to response in panic disorder.

Mavissakalian MR, Perel JM.

Psychopharmacol Bull. 1996;32(1):143-7.

PMID:
8927664
20.
21.

Life events and panic disorder/agoraphobia.

Lteif GN, Mavissakalian MR.

Compr Psychiatry. 1995 Mar-Apr;36(2):118-22.

PMID:
7758297
22.
23.

Patterns of obsessive compulsive symptoms in Tourette subjects are independent of severity.

de Groot CM, Bornstein RA, Janus MD, Mavissakalian MR.

Anxiety. 1994-1995;1(6):268-74.

PMID:
9160585
24.

Dose-response characterization of the antipanic effects of imipramine.

Mavissakalian MR, Perel JM.

Psychopharmacol Bull. 1994;30(2):171-4.

PMID:
7831451
25.

DSM-III personality disorders in generalized anxiety, panic/agoraphobia, and obsessive-compulsive disorders.

Mavissakalian MR, Hamann MS, Abou Haidar S, de Groot CM.

Compr Psychiatry. 1993 Jul-Aug;34(4):243-8.

PMID:
8348802
26.

Imipramine treatment of panic disorder with agoraphobia: the second time around.

Mavissakalian MR, Perel JM, de Groot C.

J Psychiatr Res. 1993 Jan-Mar;27(1):61-8.

PMID:
8515390
27.

Are effective antiobsessional drugs interchangeable?

Tamimi RR, Mavissakalian MR.

Arch Gen Psychiatry. 1991 Sep;48(9):857-9. No abstract available. Erratum in: Arch Gen Psychiatry 1991 Nov;48(11):1021.

PMID:
1929778
28.

Clomipramine in obsessive-compulsive disorder: clinical response and plasma levels.

Mavissakalian MR, Jones B, Olson S, Perel JM.

J Clin Psychopharmacol. 1990 Aug;10(4):261-8.

PMID:
2286699
29.

Absence of placebo response in obsessive-compulsive disorder.

Mavissakalian MR, Jones B, Olson S.

J Nerv Ment Dis. 1990 Apr;178(4):268-70.

PMID:
2319236
30.

Imipramine dose-response relationship in panic disorder with agoraphobia. Preliminary findings.

Mavissakalian MR, Perel JM.

Arch Gen Psychiatry. 1989 Feb;46(2):127-31.

PMID:
2643933
31.

Patterns of desynchrony in agoraphobia: a preliminary report.

Barlow DH, Mavissakalian MR, Schofield LD.

Behav Res Ther. 1980;18(5):441-8. No abstract available.

PMID:
7436991

Supplemental Content

Loading ...
Support Center